The authors concluded that CLDN2 plays an oncogenic role in CRC progression because the overexpression of this protein is associated with poor survival of CRC patients, and it may serve as a promising target for the treatment of patients with this malignancy [50]. The gene discussed is CLDN2; the disease is colorectal carcinoma.